Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

Source :: Plus Company Updates. February 21, 2020
Publication Year :: 2020
Abstract: MILAN: Zambon has issued the following press release: Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people's health and [...]

Subjects :: Clinical trials
Respiratory tract diseases -- Care and treatment
Hematopoietic stem cells
Medical research
Hematopoietic stem cell transplantation
Bronchiolitis -- Care and treatment
Stem cells
Stem cell transplantation
Lung diseases
Pharmaceutical industry
Diseases
General interest
News, opinion and commentary

Tools